First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
- PMID: 27288039
- PMCID: PMC5007220
- DOI: 10.1183/13993003.00637-2016
First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
Abstract
Report of the first case, concerns and challenges of treatment of severe XDR-TB with both delamanid and bedaquiline
Conflict of interest statement
Conflicts of Interest: None declared.
Comment in
-
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.Eur Respir J. 2016 Nov;48(5):1526-1527. doi: 10.1183/13993003.01207-2016. Eur Respir J. 2016. PMID: 27799400 No abstract available.
-
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.Eur Respir J. 2016 Nov;48(5):1527-1529. doi: 10.1183/13993003.01552-2016. Eur Respir J. 2016. PMID: 27799401 No abstract available.
References
-
- Tiberi S, D'Ambrosio L, De Lorenzo S, et al. . Tuberculosis elimination, patients’ lives and rational use of new drugs: revisited. Eur Respir J 2016; 47: 664–667. - PubMed
-
- Pontali E, Sotgiu G, D'Ambrosio L, et al. . Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J 2016; 47: 394–402. - PubMed
-
- Sotgiu G, Pontali E, Centis R, et al. . Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Rev Anti Infect Ther 2015; 13: 305–315. - PubMed
-
- Esposito S, D'Ambrosio L, Tadolini M, et al. . ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014; 44: 811–815. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources